+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-11-06Number of Pages: 78

Hypertrophic Cardiomyopathy Therapeutics Market - (By Drug Class: Beta Adrenergic Blocking Agents, Calcium Channel Blocker, Antiarrhythmic Agents, and Anticoagulants) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023

Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM. Prevalence of HCM is higher among African-Americans compared to other races. The global hypertrophic cardiomyopathy therapeutics market was valued at USD 1,216.3 million in 2014 and is projected to reach USD 1,378.4 million by 2023, expanding at a CAGR of 1.4% during the forecast period.

The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy therapeutics market. Calcium channel blockers was the largest segment in 2014, although beta adrenergic blocking agents were the first choice for treatment of obstructive and non-obstructive HCM. Price of calcium channel blockers is higher than beta adrenergic blocking agents; hence, in terms of revenue, calcium channel blockers dominated the hypertrophic cardiomyopathy therapeutics market in 2014. A similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a CAGR of 1.8% from 2015 to 2023.

Geographically, the hypertrophic cardiomyopathy therapeutics market has been segmented into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). The market is primarily concentrated in the U.S., followed by Europe. The U.S. was the most attractive market for hypertrophic cardiomyopathy therapeutics in 2014, with more than 30% share of the global market. Europe accounted for the second-largest share of the global market in 2014. In 2014, the U.S. and Europe primarily dominated the hypertrophic cardiomyopathy therapeutics market due to modern healthcare infrastructure, increasing sedentary lifestyle among the youth, and rising obese population. Additionally, high awareness about HCM in developed countries boosts the market growth. North America is expected to continue its dominance during the forecast period. Asia Pacific was the fastest growing markets due to rising disease prevalence, developing healthcare infrastructure, and increasing awareness about cardiac complications in these regions. However, technological advancements in devices such as defibrillators and pacemakers are estimated to hamper market growth. This, in turn, would restrict the uptake of hypertrophic cardiomyopathy drugs. Thus, market leaders are recommended to focus on the development of new drugs or combination drugs that are specifically targeted toward hypertrophic cardiomyopathy in order to gain competitive advantage in the market.

AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

 

hypertrophic-cardiomyopathy-therapeutics-market

 

 

1. Preface
     1.1. Report Description
     1.2. Market Segmentation
     1.3. Research Methodology

2. Executive Summary
     2.1. Hypertrophic Cardiomyopathy Therapeutics: Market Snapshot
     2.2. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Geography, 2014 & 2023 (Value %)
     2.3. Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class, 2014 (US$ Mn)

3. Hypertrophic Cardiomyopathy Therapeutics Market - Industry Analysis
     3.1. Introduction
     3.2. Epidemiology and Prognosis: Hypertrophic Cardiomyopathy
     3.3. Market Dynamics
            3.3.1. Drivers
                     3.3.1.1. Driver 1: Increasing prevalence of chronic cardiovascular diseases to increase demand for effective treatments
                     3.3.1.2. Driver 2: High awareness associated with HCM in developed countries
            3.3.2. Restraints
                     3.3.2.1. Restraint 1: Rising technological upgradation in devices such as defibrillators and pacemakers
            3.3.3. Opportunities
                     3.3.3.1. Opportunity 1: Targeted therapy for hypertrophic cardiomyopathy
     3.4. Market Attractiveness Analysis - Hypertrophic Cardiomyopathy Therapeutics Market, by Geography, 2014
     3.5. Competitive Landscape 
     3.6. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Key Players, 2014 (%)

4. Market Segmentation – By Drug
     4.1. Introduction
            4.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
     4.2. Global Beta Adrenergic Blocking Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.3. Global Calcium Channel Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.4. Global Antiarrhythmic Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.5. Global Anticoagulants  Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Pipeline Analysis
     5.1. Overview
     5.2. Phase II and Phase I Clinical Trials

6. Market Segmentation – By Geography
     6.1. Introduction
            6.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Region, 2013–2023 (US$ Mn)
     6.2. North America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.2.1. U.S. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.2.2. Canada Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.3. Europe Hypertrophic Cardiomyopathy Therapeutics Market – Revenue, by Country, 2013–2023 (US$ Mn)
            6.3.1. U.K. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.3.2. Germany Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.3.3. Rest of Europe Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.4. Asia Pacific Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.4.1. India Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.4.2. Japan Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.4.3. Rest of APAC Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.5. Rest of the World Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.5.1. Latin America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.5.2. Middle East Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.5.3. Africa Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)

7. Recommendations
     7.1. Recommendation 1: Companion diagnostics would help to increase the diagnostic rate and ultimately the drugs market 

8. Company Profiles
     8.1. Astra Zeneca plc
     8.2. Concordia Healthcare Corp.
     8.3. Gilead Sciences, Inc.
     8.4. Merck & Co., Inc.
     8.5. Mylan N.V.
     8.6. Novartis AG
     8.7. Pfizer, Inc. 
     8.8. Sanofi S.A.
     8.9. Teva Pharmaceutical Industries Ltd

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Modern healthcare infrastructure, increasing sedentary lifestyle in young population and rising obese population are expected to propel the global hypertrophic cardiomyopathy therapeutics market.

The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.  

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been segmented into four major categories: Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Antiarrhythmic Agents, and Anticoagulants. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global hypertrophic cardiomyopathy therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, India, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East, Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global hypertrophic cardiomyopathy therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG

The global hypertrophic cardiomyopathy therapeutics market is segmented as follows:

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Antiarrhythmic Agents
  • Anticoagulants  

Global Hypertrophic Cardiomyopathy Therapeutics, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa